Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

155.33 +3.52 (+2.32%)
Streaming Delayed Price Updated: 10:56 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
News headline image
Wall Street Braces for Impact as Delayed Jobs Report Emerges from Data Blackout
New York, NY – November 19, 2025 – Wall Street is on high alert as the highly anticipated September 2025 jobs report, a critical barometer of the nation's economic health, is finally set to be released... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
From Gilead Sciences, Inc.
Via Business Wire
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗
Via Stocktwits
News headline image
Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
Healthcare Sector Navigates Mixed Market Close: A Beacon of Stability Amidst Uncertainty
As the broader market concluded with a mixed performance on November 14, 2025, the S&P 500 Healthcare sector once again underscored its often-defensive nature, demonstrating resilience amidst an... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
1 Healthcare Stock to Own for Decades and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
News headline image
Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?
As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance,... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Gilead’s Experimental One Pill Regimen Proved Non-Inferior To Multi-Pill Regimens In Treating HIV ↗
The company now plans to submit the data from the study to regulatory authorities. 
Via Stocktwits
News headline image
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial ↗
Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy. 
Via Benzinga
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday. 
Via Chartmill
News headline image
2 Supercharged Dividend Stocks to Buy Now ↗
Innovative drugmakers often make for solid dividend stocks. These two companies are great examples. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Is the AI Rally a Bubble? Impact on Commodity Demand and Defensive Stock Rotation
As November 2025 unfolds, a subtle yet significant shift in market sentiment is becoming increasingly palpable among financial analysts and retail investors alike. What was once an almost universally... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
GBK Brand Bar and Meals on Me Host the Official Backstage Lounge at the 40th Annual Rock & Roll Hall of Fame Induction Ceremony Rehearsals
November 10, 2025 -- During rehearsals leading up to the Induction Ceremony, GBK welcomed some of the world's biggest musicians from legendary icons to today's top superstars. 
Via 24-7 Press Release
News headline image
What's going on in today's session: S&P500 movers ↗
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend ↗
Gilead's Trodelvy missed a key goal in breast cancer, while Livdelzi showed durable efficacy and safety in long-term liver disease studies. 
Via Benzinga
News headline image
Gilead Provides Update on Phase 3 ASCENT-07 Study
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns
The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
News headline image
Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions
Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market responded negatively due to ongoing concerns about oncology revenue and broader... 
Via StockStory
Topics Earnings
News headline image
3 Cash-Rich Stocks With High Growth Potential Right Now ↗
Via MarketBeat
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Gilead Sciences Inc (NASDAQ:GILD) Appears as a Decent Value Stock ↗
Gilead Sciences (GILD) appears undervalued with a low P/E ratio, strong profitability, no debt, and a solid dividend, fitting classic value investing principles. 
Via Chartmill
News headline image
Moderna Earnings: What To Look For From MRNA
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Thursday before the bell. Here’s what investors should know. 
Via StockStory
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.